[Therapeutic effect of defibrase in chronic glomerulonephritis with chronic renal failure]

Insights

Defibrase, derived from viper venom, improved kidney function in chronic renal failure patients by reducing fibrin deposition and thromboembolic lesions. This treatment alleviated uremia symptoms and improved renal parameters.

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Context:

  • Chronic glomerulonephritis (CGN) progressing to chronic renal failure (CRF) is characterized by decreased fibrinolysis and glomerular fibrin deposition, leading to thromboembolic lesions.
  • This study investigates a novel therapeutic approach for CGN patients with CRF.

Purpose:

  • To evaluate the efficacy and safety of defibrase, a fibrinolytic agent derived from viper venom, in treating chronic renal failure (CRF) secondary to chronic glomerulonephritis (CGN).

Summary:

  • 46 CGN patients with CRF received defibrase (0.025 units/kg) infusions every 3 days for 6 treatments.
  • Post-treatment, patients showed reduced Blood Urea Nitrogen (BUN) and serum creatinine, improved creatinine clearance, and alleviation of uremic symptoms.
  • Hemoglobin levels increased, urinary protein excretion decreased, and hypertension was controlled in most patients when combined with captopril. Increased urinary output correlated with therapeutic effect.

Impact:

  • Defibrase therapy may improve renal function in CGN patients with CRF by resolving glomerular fibrin deposition and thromboembolic lesions.
  • The study suggests potential benefits in managing uremia and associated complications, although careful dose determination is needed due to bleeding risks.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...